Business
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases
-- Executive Leadership Team Established with Demonstrated Success in Clinical, Regulatory and Commercial Development -- SOUTH SAN FRANCISCO,
About this update from Twist Bioscience Corporation
[{"type":"text","content":"\n-- Executive Leadership Team Established with Demonstrated Success in Clinical, Regulatory and Commercial Development --\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nTwist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of Twist Bioscience, that neutralizes all known variants of concern of the SARS-CoV-2 virus in preclinical studies. In addition, Revelar will have the ability to leverage the antibody discovery and optimization platform of Twist Biopharma to license additional antibodies for up to five targets over the next four years.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005421/en/\nEmily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience commented: “In launching Revelar Biotherapeutics, we assembled an experienced executive leadership team with a proven track record of successful clinical and corporate development together with access to a series of antibody therapeutic leads. This transaction allows Twist to participate in the rapid advancement of therapeutic antibodies while remaining focused on our current opportunities in our core business as well as our biopharma and DNA data storage verticals. We look forward to having our first Twist Biopharma-discovered antibody enter clinical studies in 2022, pending the necessary requirements.”\n\n“In parallel with the development of the antibody to treat SARS-CoV-2, which we believe has the potential to be delivered subcutaneously, we intend to build a pipeline of novel therapeutics by leveraging the robust Twist Biopharma antibody discovery and optimization platform,” commented David Scheer, chairman of the board of Revelar Biotherapeutics. “Pairing Twist’s ability to identify single domain and multifunctional antibodies combined with the broad development expertise of the Revelar team sets the stage to move the needle in treating unmet medical needs.”\n\nTwist Bioscience granted a license to Revelar for the exclusive development of an antibody lead along with a series o...